All In Biotech

Drug Trial Radar · NCT03580655

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

107

Actual

Start

Nov 21, 2018

Primary completion

Dec 18, 2024

Study completion Dec 18, 2024

Sponsor

Sponsor type
Industry
First posted
Jul 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, single arm, Phase 2 study evaluating the efficacy and safety of avapritinib (BLU-285) in patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive SM (ASM), SM with associated hematologic neoplasm (SM-AHN), and mast cell leukemia (MCL)

Conditions

  • Advanced Systemic Mastocytosis
  • Aggressive Systemic Mastocytosis
  • Systemic Mastocytosis With an Associated Hematologic Neoplasm
  • Mast Cell Leukemia

Interventions

  • AvapritinibDrug

    Avapritinib tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR) Based on Modified International Working Group-Myeloproliferative Neoplasms Research and Treatment and European Competence Network on Mastocytosis (mIWG-MRT-ECNM) Response CriteriaTime frame: Baseline through Month 65

Locations

32 sites in 12 countries. Site status is shown where the registry gives one.

  • Stanford Cancer Institute

    Stanford, California

  • Rush University Medical Center

    Chicago, Illinois

  • The University of Kansas Cancer Center

    Westwood, Kansas

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York

  • Herbert Irving Comprehensive Cancer Center

    New York, New York

  • University of Pennsylvania, Abramson Cancer Center

    Philadelphia, Pennsylvania

  • University of Texas, MD Anderson Cancer Center

    Houston, Texas

  • Mays Cancer Center

    San Antonio, Texas

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • Medizinische Universität Wien, Universitätsklinik für Innere Medizin I, Klinische Abteilung für Hämatologie und Hämostaseologie

    Vienna, Austria

  • St. Michael's Hospital

    Toronto, Ontario, Canada

  • Odense University Hospital, Department of Haematology

    Odense, Denmark

  • Hôpital Necker-Enfants Malades

    Paris, France

  • CHU Toulouse - Hôpital Larrey

    Toulouse, France

  • Uniklinik RWTH Aachen, Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltranslplantation

    Aachen, Germany

  • Universitätsklinikum Hamburg-Eppendorf, Zentrum für Onkologie

    Hamburg, Germany

  • Universitätsklinikum Leipzig, Medizinische Klinik und Poliklinik I - Hämatologie und Zelltherapie, lnternistische Onkologie, Hämostaseologie

    Leipzig, Germany

  • Universitätsmedizin Mannheim III. Medizinische Klinik

    Mannheim, Germany

  • Klinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar der TU München

    Munich, Germany

  • Azienda Ospedaliero-Universitaria Careggi, CRIMM - Centro di Ricerca ed Innovazione per le Malattie Mieloproliferative

    Florence, Italy

  • A.O. OO.RR. S.Giovanni di Dio e Ruggi d'Aragona, University of Salerno

    Salerno, Italy

  • Centro Ricerche Cliniche di Verona - Azienda Ospedaliera Universitaria Integrata di Verona

    Verona, Italy

  • University Medical Center Groningen (UMCG)

    Groningen, Netherlands

  • Oslo University Hospital-Rikshospitalet, Hematology

    Oslo, Norway

  • Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii

    Gdansk, Poland

  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu, Klinice Hematologii, Nowotworów Krwi i Transplantacji Szpiku

    Wroclaw, Poland

  • lnstituto de Estudios de Mastocitosis de Castilla la Mancha, Hospital Virgen del Valle - Complejo Hospitalario de Toledo

    Toledo, Spain

  • Beatson West of Scotland Cancer Centre - NHS Greater Glasgow and Clyde

    Glasgow, United Kingdom

  • Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.